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The future of 89Zr-based immuno-PET is reliant upon the development of new 
chelators with improved stability compared to the currently used 
deferoxamine (DFO). Herein, we report the evaluation of the octadentate 
molecule DFO-HOPO (3) as a suitable chelator for 89Zr and a more stable 
alternative to DFO. The molecule showed good potential for the future 
development of a DFO-HOPO-based bifunctional chelator (BFC) for the 
radiolabelling of biomolecules with 89Zr. This work broadens the selection of 
available chelators for 89Zr in search of improved successors of DFO for 
clinical 89Zr-immuno-PET. 
An increasing interest in zirconium-89 (89Zr) for preclinical and clinical immuno-
positron emission tomography (PET) is owed to its favourable decay 
characteristics (t1/2 = 78.4 h, β+ = 22.8%, Eβ+max = 901 keV) for the radiolabelling 
of antibodies which have long biological half-lives.1-4 Currently, deferoxamine 
(DFO) is the chelator most commonly used to radiolabel biomolecules with 89Zr.5 
DFT modelling showed that the coordination sphere in the Zr-DFO complex 
consists of the Zr4+ cation, six donor atoms belonging to the DFO molecule, and 
other two coordination sites being occupied by water molecules.6, 7 As a result of 
this incomplete coordination of 89Zr by the hexadentate DFO molecule, the 89Zr-
DFO complex undergoes a certain degree of demetallation in vivo with the released 
89Zr taken up by the bone.8 This is of concern because bone uptake of free 89Zr4+ is 
undesirable owing to the high radiation dose to bone marrow; furthermore this 
background uptake can confound image acquisition of bone malignancies such as 
bone metastases. To solve the instability, different strategies have been 
investigated. Alternative hexadentate macrocycles (i.e Fusarinine C) and 
hydroxypyridinone-based compounds (i.e. CP256) have been produced and tested 
but showed either no improvement or poorer stability in vivo when compared to 
DFO.9, 10 Additionally, a variety of either linear or macrocyclic octadentate 
chelators have been developed with structures hinged around hydroxamic acid or 
hydroxypyridinone moieties which resulted in 89Zr-complexes displaying either 
increased or decreased stability compared to DFO.11-16 White et al. described the 
use of a DFO-1-hydroxy-2-pyridone ligand (DFO-HOPO) as an effective 
sequestering agent for the treatment of plutonium (IV) intoxication (Fig. 1).17 The 
authors showed that the addition of one 1,2-HOPO molecule to DFO produced a 
low toxicity octadentate chelator which yielded very stable complexes with Pu(IV) 
at physiological pH. Herein, we report an updated synthesis of DFO-HOPO (3) 
which was then evaluated as an octahedral ligand for 89Zr. The stability of the 
radiocomplex was tested in vitro and in vivo and compared to 89Zr-DFO in order to 
confirm 3 as a viable alternative to the chelators for 89Zr already described in the 
literature.  
The synthesis of DFO-HOPO (3) was adapted from a literature procedure.17 In 
brief, commercially available DFO was reacted with hydroxamic acid chloride (2) 
and the product (3) was isolated by semi-preparative RP-HPLC (Scheme S1). No 
protection of the N-hydroxyl group of 1 was necessary. To determine and 
characterise the coordination capabilities of the chelator, the non-radioactive natZr 
complex of DFO-HOPO (natZr-3) was prepared in macroscopic scale by mixing the 
chelator with ZrCl4 at room temperature. Showing the value of 784.247 m/z, the 
high resolution mass spectrometry (HRMS) analysis of natZr-3 confirmed the 
expected complex mass to indicate a metal-to-ligand binding ratio of 1:1. 
Examination by RP-HPLC showed the elution of natZr-3 as a single peak at 7:20 
min:sec, ca 33 seconds before HOPO-DFO (3). The coordination of the metal ion 
by the chelator was further confirmed by infrared spectrometry (IR) analysis which 
showed a red-shift in the main carbonyl stretching band from ca 1620 to ca 1600 
cm-1. Additional characterisation of the complex by ultraviolet-visible 
spectroscopy (UV-Vis) showed no detectable difference between the absorption 
spectra of natZr-3 and 3. Moreover, NMR analysis of the natZr complex could not be 
performed due to its poor solubility in any solvent. 
To verify the steric and electronic ability of 3 to form a Zr(IV) octadentate chelate, 
density functional theory (DFT) calculations were carried out. The optimised 
geometry (based on the lower energy conformation) shows the metal centre 
coordinated to eight oxygen atoms of the chelator (Fig. 2). The Zr-O bond 
distances were in the range of 2.14 – 2.36 Å, in agreement with values reported in 
the literature for similar complexes.11, 12 In common with 89Zr-DFO, the 
preparation of 89Zr-3 was performed as previously described in the literature by 
incubating the chelator with a neutralised 89Zr solution at room temperature for 1 h 
(pH 7) to guarantee a quantitative (>99%) radiolabelling which could be achieved 
up to 20 MBq/nmol even at low concentration of the chelators (3-8 µM).18 All 
reactions were monitored by radioactive instant thin layer chromatography (radio-
ITLC). A variety of mobile and stationary phases were tested to find the optimum 
analytical conditions for both 89Zr-3 and 89Zr-DFO, which was used as a 
comparison. The elution profiles of both the radioactive complexes were affected 
by the type of stationary phase employed, and only the positively charged 89Zr-
DFO (consequence of the hexadentate chelation of 89Zr) was influenced also by the 
mobile phase pH, when SG-ITLC strips were used. The results suggest that, 
differently from 89Zr-DFO, 89Zr-3 is present in solution as a neutral complex, 
achievable through the octadentate chelation of 89Zr. This finding further advocates 
the involvement of the 1,2-HOPO moeity of 3 in the coordination of the metal 
centre. Enabling the elution of 89Zr-3 and the 89Zr-DFO as well defined and 
separated bands (Rf of 0.6 and 0.1 respectively on SG-ITLC strips), ammonium 
acetate (0.1 M, pH 7) was used as mobile phase for the ITLC analysis. 
Interestingly, the radio-ITLC of 89Zr-3 revealed the presence of two well-separated 
spots (Rf of ca 0.6 and 0.1); the relative intensity of the spots was dependent on the 
specific activity of the product (i.e. concentration of the chelator) and on time. By 
lowering the specific activities of the product, with a consequent increase of the 
concentration of 3, a decrease of the band having Rf = 0.1 was observed. After 24 
hours at ambient temperature, only the band having Rf = 0.6 was detected. 
Performing the radiolabelling reaction at 80°C reduced the quantity of the product 
eluting with an Rf = 0.1 but did not prevent it from forming. These observations 
suggest that the two bands represent two different forms of the 89Zr-3 complex; an 
initial transitional kinetic product which converted into a final thermodynamically 
stable product. Examination of the chromatographic data of 89Zr-3 could help 
explain the phenomenon; the transitional product was detected at the origin of the 
radio-ITLC strip (Rf = 0.1 at pH 7) suggesting it was charged (similarly to 
hexacoordinated 89Zr-DFO), possibly as the result of incomplete coordination of 
the radiometal. With an Rf = 0.6 (at pH 7), the thermodynamically stable final 
product was most likely neutral, a condition which would be achieved by the 
complete chelation of 89Zr by octadentate 3. Moreover, radio-HPLC analysis of 
89Zr-3 after 24 hours showed only one product (corresponding to the band with Rf 
= 0.6 on radio-ITLC) having an elution profile very similar to that of natZr-3 
suggesting a similar identity as an octadentate complex. Importantly, no 89Zr was 
released during the transition. 
The stability of 89Zr-3 was initially assessed by a simple radio-ITLC analysis using 
an acidic buffer (pH 2) as mobile phase. Differently from 89Zr-DFO (14.4 ± 4.65% 
radioactivity not associated with DFO), 89Zr-3 showed no demetallation as a result 
of the enhanced coordination of the metal centre by the octadentate ligand. To 
mimic what might happen in vivo, a challenge assay assessed the stability of 89Zr-3 
to transchelation in the presence of a large excess of either EDTA or DFO (pH 7). 
In both challenges, 89Zr-3 showed no transchelation with >99% intact complex 
after 7 days (Table 1). By comparison, 89Zr-DFO demonstrated transchelation 
toward EDTA with 65.5 % of intact complex after 7 days (Table 1). Moreover, a 
complete transmetallation of 89Zr-DFO towards 3 was achieved in a matter of 
hours. Further experiments aiming to test the inertness of 89Zr-3 were performed in 
mouse serum. With >99 % intact complex after incubation at 37°C for 7 days, 89Zr-
3 showed a higher stability compared to 89Zr-DFO (90.6% intact complex) (Table 
1). 
PET imaging and comparative biodistribution studies were performed in healthy 
mice for 89Zr-3 and 89Zr-DFO. At 1 h p.i. of 89Zr-3, the radioactivity was observed 
mainly in the bladder and intestine; some activity was also visible in the gall 
bladder. At 4 and 24 h p.i., most of the residual radioactivity was in the gut. These 
observations indicate a rapid renal clearance together with a certain extent of a 
slower hepatobiliary excretion. The hydrophilicity of the complexes is an 
important physiochemical property which regulates their distribution, metabolism, 
and elimination in vivo. The LogD7.4 of neutral complex 
89Zr-3 was found to be -
0.87 ± 0.03 which indicates a less hydrophilic character than the positively charged 
89Zr-DFO (-3.0 ± 0.01) and can explain the clearance pathway.9 After 24 h, the 
radioactivity level was minimal therefore no additional imaging studies at longer 
time points were carried out. Importantly, no uptake of 89Zr in the bone was 
observed at any time point (Fig. 3). 
Corroborating the PET images, the biodistribution studies clearly showed the 
participation of both the renal and hepatobiliary systems in the clearance of 89Zr-3 
(Fig. 4). Most of the radioactivity had already cleared through the kidneys at 1 h 
p.i. (1.39 ± 0.1%ID/g), while at 4h p.i. the residual activity was localised in the gut 
(mostly small intestine with 0.898 ± 0.252% ID/g). Differently from 89Zr-DFO 
(0.93 ± 0.11%ID/g still present in the kidneys), 89Zr-3 was almost completely 
cleared from the body at 24 h p.i. Although the values are quite low, 89Zr-DFO 
showed ca 10-fold higher activity accumulation in the bone than 89Zr-3 at 24 h p.i 
(0.037 ± 0.002 and 0.004 ± 0.001 for 89Zr-DFO and 89Zr-3 respectively). This 
phenomenon could be correlated to either the higher level of radioactivity still 
present in the animals injected with 89Zr-DFO or to an improved in vivo stability of 
89Zr-3 compared to 89Zr-DFO. 
In summary, the 89Zr-3 complex exhibited improved stability compared to 89Zr-
DFO in both challenge assays and in serum; the capability and favourability of 3 to 
form a stable chelate was clearly demonstrated by the complete transchelation of 
89Zr from 89Zr-DFO in ca 3 h. The in vivo studies showed that 89Zr-3 cleared the 
body via the renal and hepatobiliary systems. However, once conjugated to a 
biomolecule the pharmacokinetics of the final radioconjugate will depend mainly 
on the biomolecule itself. Importantly, the straightforward synthesis of 3 from the 
commercially available DFO is amenable to allow the synthesis of a bifunctional 
chelator which is currently underway in our laboratory. The promising DFO-
HOPO molecule is a valuable addition to the selection of available chelators for 
89Zr in search of successful successors of DFO for clinical immuno-PET 
applications based on important characteristics such as synthesis, chelate stability 
and in vivo pharmacokinetics. 
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Figures 
 
Figure 1. Structure of DFO-HOPO (3) containing three hydroxamic acid and one hydroxypyridone 
moiety for coordinating 89Zr4+. 
 
 
Figure 2. The DFT optimised structure of 89Zr-3. (atom colour: white = hydrogen; 
grey = carbon; blue = nitrogen; red = oxygen; cyan = zirconium). 
   Fraction of intact complex (% ± SD) 
 Complex Competitor 0 min 1 h 3 h 1 d 3 d 7 d 
A 
89Zr-3 
EDTA >99 >99 >99 >99 >99 >99 
DFO >99 >99 >99 >99 >99 >99 
89Zr-DFO 
EDTA >99 >99 >99 75.63±3.07 63.1±0.75 65.5±4.42 
3 >99 35.8±9.8 4.1±2.35 0 0 0 
B 
89Zr-3 Mouse Serum >99 -- >99 >99 >99 >99 
89Zr-DFO Mouse Serum >99 -- >99 97.7±0.53 94.7±0.78 90.6±1.75 
 
Table 1. The stability of 89Zr-3 and 89Zr-DFO was tested against transchelation in 
the presence of an excess of competitor chelator over seven days (pH 7). The 
controls (complexes in solution without competitor) show high stability (>99% 
intact complex) (A). The stability of the 89Zr-complexes was also tested in mouse 
serum over seven days (B). 
 
 
Figure 3. Coronal PET images of 89Zr-3 in healthy mice at 1, 4 and 24 h p.i. The 
white arrows indicate the gall bladder (a), intestine (b) and the bladder (c). An 
almost complete clearance of 89Zr-3 was observed after 24 h. 
 
 Figure 4. Biodistribution data for 89Zr-3 and 89Zr-DFO at 1, 4 and 24 h p.i. in 
selected organs. SI = small intestine; LI = large intestine. 
